Clinical and genomic analyses of neuroendocrine neoplasms of the breast

被引:8
|
作者
Wei, Yani [1 ,2 ]
Ke, Xuexuan [1 ]
Yu, Jiaxiu [1 ]
Jing, Qiuyang [3 ]
Bu, Hong [1 ,2 ]
Zeng, Xiangfei [1 ]
Wei, Bing [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, Inst Clin Pathol, West China Hosp, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp 2, Dept Pathol, Chengdu, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
SMALL-CELL CARCINOMA; CANCER; DIFFERENTIATION; MEKK4; EXPRESSION; PROGNOSIS; SURVIVAL;
D O I
10.1038/s41379-021-00965-w
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Breast neuroendocrine neoplasms (NENs) constitute a rare histologic subtype that includes both neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this study, we aimed to gain insight into the clinical and molecular characteristics of NENs of the breast. NEN and paired distant normal fresh tissues and clinicopathological data were obtained from 17 patients with NENs, and clinicopathological data were collected from 755 patients with invasive breast carcinomas of no special type (IBCs-NST). We compared the clinicopathological characteristics of NENs and IBCs-NST and performed whole-exome sequencing (WES) of both NEN and paired normal tissues. Compared with the IBC-NST patients, the NEN patients had a higher mean age, lower clinical stage, and lower pathological nodal (pN) stage (P < 0.001, P < 0.001, and P = 0.017, respectively). The most frequently mutated gene in NENs was KMT2C (3/17, 17.6%). NENs had copy number variations (CNVs) of 8q, 11q, and 17q amplification and 17q and 11q deletion and harbored the following specific genes related to tumorigenesis: (i) suppressor genes with loss of heterozygosity (LOH) such as ACE (2/17, 11.8%); (ii) tumor driver genes such as GATA3 (2/17, 11.8%); and (iii) susceptibility genes such as MAP3K4 (17/17, 100%) and PDE4DIP (17/17, 100%). The oncogenic/likely oncogenic mutations of NETs in PI3K pathway genes (50.0%, 18.2%; P < 0.001) and MAPK signaling pathway genes (83.3%, 18.2%; P = 0.035) affected higher proportions than those of NECs. In conclusion, this study provides certain clinical and molecular evidence supporting NENs as a distinct subtype of breast cancer and provides some potential molecular features for distinguishing NETs from NECs.
引用
收藏
页码:495 / 505
页数:11
相关论文
共 50 条
  • [41] Spectral CT in clinical routine imaging of neuroendocrine neoplasms
    Boening, G.
    Adelt, S.
    Feldhaus, F.
    Fehrenbach, U.
    Kahn, J.
    Hamm, B.
    Streitparth, F.
    CLINICAL RADIOLOGY, 2021, 76 (05) : 348 - 357
  • [42] An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide
    Bevere, Michele
    Masetto, Francesca
    Carazzolo, Maria Elena
    Bettega, Alice
    Gkountakos, Anastasios
    Scarpa, Aldo
    Simbolo, Michele
    DIAGNOSTICS, 2023, 13 (17)
  • [43] The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective
    Marien, Laura
    Islam, Odeta
    Chhajlani, Siddharth
    Lybaert, Willem
    Peeters, Marc
    Van Camp, Guy
    de Beeck, Ken Op
    Vandamme, Timon
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1833 - 1851
  • [44] Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects
    Koumarianou, Anna
    Kaltsas, Gregory
    Kulke, Matthew H.
    Oberg, Kjell
    Strosberg, Jonathan R.
    Spada, Francesca
    Galdy, Salvatore
    Barberis, Massimo
    Fumagalli, Caterina
    Berruti, Alfredo
    Fazio, Nicola
    NEUROENDOCRINOLOGY, 2015, 101 (04) : 274 - 288
  • [45] Clinical Epidemiology Study of Gastric Neuroendocrine Neoplasms in China
    Zhang, Y.
    Fan, J. H.
    Chen, Y.
    Shi, S. S.
    Yuan, X. H.
    Jiang, L. M.
    Ma, L.
    Chi, Y.
    Qiao, Y. L.
    NEUROENDOCRINOLOGY, 2016, 103 : 35 - 35
  • [46] Reply to: Neuroendocrine neoplasms of the breast: diagnostic confusion and future perspectives
    Jasna Metovic
    Anna Sapino
    Isabella Castellano
    Virchows Archiv, 2023, 482 : 931 - 932
  • [47] Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature
    Ozaki, Yukinori
    Miura, Sakiko
    Oki, Ryosuke
    Morikawa, Teppei
    Uchino, Keita
    CANCERS, 2022, 14 (01)
  • [48] Neuroendocrine neoplasms of the breast showing peculiar forms of recurrence and/or metastasis
    Kawasaki, T.
    Sapino, A.
    Ishida, M.
    Tada, T.
    Matsuya, H.
    Nakagomi, H.
    Oyama, T.
    Muramatsu, C.
    Ichikawa, J.
    Saitoh, M.
    Kondo, T.
    Katoh, R.
    Sugai, T.
    Nakamura, Y.
    Kaira, K.
    VIRCHOWS ARCHIV, 2020, 477 : S48 - S48
  • [49] Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review
    Ozdirik, Burcin
    Kayser, Antonin
    Ullrich, Andrea
    Savic, Lynn J.
    Reiss, Markus
    Tacke, Frank
    Wiedenmann, Bertram
    Jann, Henning
    Roderburg, Christoph
    CANCERS, 2020, 12 (03)
  • [50] Neuroendocrine Neoplasms
    Schott, M.
    Oberg, K.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (12) : 823 - 824